Le et al. [24] in a phase II clinical trial, after the administration of Pembrolizumab (an anti-PD-L1 Mab), showed a partial objective response rate of 40% and 0% for dMMR and pMMR CRC patients, respectively. Here, CD274 is linked to colorectal carcinoma.